Products
Boserolimab Biosimilar Monoclonal Antibody (CD27) for Research
Cat No.: GMP-Bios-INN-1108
Anti-TNFRSF7/CD27 therapeutic antibody (Pre-made Boserolimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Boserolimab (development code MK-5890) is a monoclonal antibody targeting CD27. It is developed by Bionovion and Merck Sharp & Dohme for non-small cell lung cancer, small cell lung cancer. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1108-1mg | 1mg | 3090 |
| GMP-Bios-INN-1108-10mg | 10mg | |
| GMP-Bios-INN-1108-100mg | 100mg | |
| GMP-Bios-INN-1108-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Boserolimab biosimilar, Whole mAb, Anti-TNFRSF7/CD27 Antibody: Anti-CD27/CD27 antigen/CD27L receptor/T-cell activation antigen CD27 therapeutic antibody |
| INN Name | Boserolimab |
| Target | TNFRSF7/CD27 |
| Format | Whole mAb |
| Derivation | na |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | 8ds5:CB |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | Bionovion;Merck Sharp & Dohme |
| Conditions Approved | na |
| Conditions Active | Non-small cell lung cancer;Small cell lung cancer |
| Conditions Discontinued | Solid tumours |
| Production | na |
| Development Tech | na |
